Thus, patients with lower risk MDS, and ≥3% CD117 expressing erythroid precursors are strongly associated with a favorable response to ESA treatment, transfusion independence and longer progression free survival (PFS) (178). Here, KIT is linked to myelodysplastic syndrome.